The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Update of the guidelines for lupus anticoagulant detection
Open accessAbstract
One of the conclusions of the subcommittee meeting on Lupus Anticoagulant/Phospholipid dependent antibodies, held in Geneva on 2007, was the need to update the guidelines on Lupus Anticoagulant (LA) detection. Particular emphasis was given to several aspects discussed in this official communication. A new paragraph is dedicated to the patient selection, and aims to minimize inappropriate requests for LA testing. Modalities for blood collection and processing are fully delineated and the choice of tests is limited to dRVVT and a sensitive aPTT. Calculation of cut-off values for each diagnostic step are clearly stated. A final paragraph reports the interpretation of the results in general and in particular situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, persistently positive LAC and/or moderate/high Sapporo criteria aPL Abs (aCL IgG or IGM, or anti-b2GPI IgG or IgM) (10) were associated with HCQ use, OR 0.24 (0.06, 0.94), p=0.04”
From Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus (2013) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last update of the guidelines for LA detection by the International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (ISTH-SSC) in 2009 12 has proven useful in achieving greater uniformity in performance and interpretation of LA testing.”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, on other points, including testing in patients on anticoagulation, cutoff values, and calculation and interpretation of results, there was uncertainty or lack of agreement.12,15”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For samples from patients with no other causes of clotting time prolongation and LA assay confirmatory test results within reference intervals, the increasingly popular paradigm of integrated testing is sufficient to detect the presence of LA without performing the mixing test at all.6, 7, 8, 9, 26, 27, 28, 31, 33, 34”
From Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mixing test is mainly to discriminate between the presence of an inhibitor and coagulation factor deficiencies such as those occurring in patients on conventional oral anticoagulants/vitamin K antagonists (VKA).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines recommend mixing tests are interpreted with either a mixing test specific cut‐off (MTC) or the index of circulating anticoagulant (ICA).”
The cited source says what the claim attributes to it.
In the citing paper
“There is no single test to detect all LA1, 6, 7, 8 and guidelines recommend performance of two different tests that represent different assay principles, the diluted Russell's viper venom time (dRVVT) and a LA‐sensitive activated partial thromboplastin time (APTT).6, 7, 8”
The cited source says what the claim attributes to it.
In the citing paper
“LA positivity was determined following the Scientific and Standardization Committee (SSC)/International Society on Thrombosis and Hemostasis (ISTH) recommendations at the time of testing.11,13”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The lupus anticoagulant assay (LA) followed international guidelines for the performance of this functional assay (54).”
From Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA (2019) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“According to ISTH/SSC (1) and CLSI (2) guidelines LAC identification should include three steps: screening for prolongation in a phospholipid-sensitive test, mixing with normal plasma to identify failure to correct and confirmation through result shortening in a phospholipid-rich test, (though in slightly different priority with CLSI).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Results were expressed as normalized ratios and interpreted according to in-house calculated cut-off values calculated with the 99th percentile (1).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Testing patients during VKA or other anticoagulant therapy for LAC remains a contentious issue and has been discouraged by official guidelines (1, 2) because of interpretational problems affecting the mixing test (8-10).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Because there is no single assay sensitive to all LA antibodies, at least 2 coagulation tests based on different assay principles are recommended for LA detection [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Various interpretation indices, including percentage of correction (%Correct), screen-to-confirm ratio (SCR), and normalized SCR (NSCR), are suggested to determine the presence of LA in these phospholipid-dependent assays [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Laboratory tests for LA detection comprise complex and multistep coagulation testing procedures, including screening, confirmatory, and mixing tests [[11], [12], [13]], and heterogeneity in these is an important cause of interlaboratory variation.”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The diluted Russell’s viper venom time (dRVVT) assay is the first recommended test for detecting LA due to its high sensitivity and specificity [14], while the LA-sensitive activated partial thromboplastin time (aPTT) assay can be used as a secondary test [[11], [12], [13], [14]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“LAC was determined using the STA-R Evolution Coagulation Analyzer (Diagnostica Stago, Asnières-sur-Seine, France) according to ISTH guidelines 1 applying dilute Russell ' s viper venomtime (dRVVT Screen and dRVVT Confirm, Diagnostica Stago, Asnières-sur-Seine, France) and a sensitive activated partial thromboplastin time (aPTT) with silica as an activator (PTT-LA, Diagnostica Stago, Asnières-sur-”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“This study supports the dRVVT as the preferred assay to detect LAC. 1”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“and LAC was performed according to the ISTH guidelines. 1,34”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“LA was determined using two clotting assays as recommended by the 2009 International Society on Thrombosis and Haemostasis (ISTH) guidelines, 21 which were applicable at the time of the study: APTT by Diagnostica Stago and dRVVT by HYPHEN BioMed. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“However, the samples were analyzed before the publication of these new guidelines and therefore interpreted according to the guidelines that were applicable at this time. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The majority of survey participants indicated that the number should be at least 40, which seems reasonable to guarantee an overall normal clotting factor activity. 12”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationBrandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Rand, J. H., Wu, X.-X., Quinn, A. S., Chen, P. P., Hathcock, J. J., & Taatjes, D. J. (2008) · Blood · doi:10.1182/blood-2008-03-144204 · Cited by 215
Self-citationDetection and Quantitative Evaluation of Lupus Circulating Anticoagulant Activity
Rosner, E., Pauzner, R., Lusky, A., Modan, M., & Many, A. (1987) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651083 · Cited by 188
Galli, M., Finazzi, G., Bevers, E. M., & Barbui, T. (1995) · Blood · doi:10.1182/blood.v86.2.617.bloodjournal862617 · Cited by 146
Self-citationA Hexagonal (II) Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Identification
Triplett, D. A., Barna, L. K., & Unger, G. A. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649671 · Cited by 132
The Textarin/Ecarin Ratio: A Confirmatory Test for Lupus Anticoagulants
Triplett, D. A., Stocker, K. F., Unger, G. A., & Barna, L. K. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649701 · Cited by 110
Jennings, I., Kitchen, S., Woods, T. A. L., Preston, F. E., & Greaves, M. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656080 · Cited by 103
Meijer, P., Vermylen, J., & Arnout, J. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614601 · Cited by 96
Cited by
Sorted by citations
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Pengo, V., Denas, G., Zoppellaro, G., Jose, S. P., Hoxha, A., Ruffatti, A., Andreoli, L., Tincani, A., Cenci, C., Prisco, D., et al. (2018) · Blood · doi:10.1182/blood-2018-04-848333 · Cited by 822
Self-citationDiagnosis and management of the antiphospholipid syndrome
Garcia, D., & Erkan, D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705454 · Cited by 819
Guidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740
Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340232 · Cited by 468
Self-citationDevreese, K. M. J., de Groot, P. G., de Laat, B., Erkan, D., Favaloro, E. J., Mackie, I., Martinuzzo, M., Ortel, T. L., Pengo, V., Rand, J. H., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15047 · Cited by 467
Self-citationSchreiber, K. I., Sciascia, S., de Groot, P. G., Devreese, K. M. J., Jacobsen, S., Ruiz‐Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 445
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
Gu, S. X., Tyagi, T., Jain, K., Gu, V. W., Lee, S. H., Hwa, J. M., Kwan, J. M., Krause, D. S., Lee, A. I., Halene, S., et al. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00469-1 · Cited by 429
Cohen, H., Hunt, B. J., Efthymiou, M., Arachchillage, D. R. J., Mackie, I. J., Clawson, S., Sylvestre, Y., Machin, S. J., Bertolaccini, M. L., Ruiz-Castellano, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30079-5 · Cited by 410
Yalavarthi, S., Gould, T. J., Rao, A. N., Mazza, L. F., Morris, A. E., Núñez‐Álvarez, C. A., Hernández‐Ramírez, D. F., Bockenstedt, P. L., Liaw, P. C., Cabral, A. R., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39247 · Cited by 397
Lockshin, M. D., Kim, M., Laskin, C. A., Guerra, M., Branch, D. W., Merrill, J., Petri, M., Porter, T. F., Sammaritano, L., Stephenson, M. D., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34402 · Cited by 388
Intagliata, N. M., Caldwell, S. H., & Tripodi, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.265 · Cited by 369
Self-citationOrdi-Ros, J., Sáez-Comet, L., Pérez-Conesa, M., Vidal, X., Riera-Mestre, A., Castro-Salomó, A., Cuquet-Pedragosa, J., Ortiz-Santamaria, V., Mauri-Plana, M., Solé, C., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0291 · Cited by 324
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 299
Self-citationErkan, D., Vega, J., Ramón, G., Kozora, E., & Lockshin, M. D. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37759 · Cited by 284
Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH
Devreese, K. M. J., Ortel, T. L., Pengo, V., & de Laat, B. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13976 · Cited by 269
Self-citationRand, J. H., Wu, X.-X., Quinn, A. S., Ashton, A. W., Chen, P. P., Hathcock, J. J., Andree, H. A. M., & Taatjes, D. J. (2010) · Blood · doi:10.1182/blood-2009-04-213520 · Cited by 253
Self-citationMeng, H., Yalavarthi, S., Kanthi, Y. M., Mazza, L. F., Elfline, M. A., Luke, C. E., Pinsky, D. J., Henke, P. K., & Knight, J. S. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39938 · Cited by 236
Testing for Antiphospholipid antibodies with Solid Phase Assays: guidance from the SSC of the ISTH
Devreese, K. M. J., Pierangeli, S. S., de Laat, B., Tripodi, A., Atsumi, T., & Ortel, T. L. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12537 · Cited by 224
Self-citationCerebral venous thrombosis: a practical guide
Ulivi, L., Squitieri, M., Cohen, H., Cowley, P., & Werring, D. J. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002415 · Cited by 217
Arnaud, L., Mathian, A., Ruffatti, A., Erkan, D., Tektonidou, M., Cervera, R., Forastiero, R., Pengo, V., Lambert, M., Martinez-Zamora, M. A., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.014 · Cited by 215
Self-citationThe clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ünlü, O., Zuily, S., & Erkan, D. (2015) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0085 · Cited by 212
Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances
Sciascia, S., Amigo, M., Roccatello, D., & Khamashta, M. A. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.124 · Cited by 216
Saccone, G., Berghella, V., Maruotti, G. M., Ghi, T., Rizzo, G., Simonazzi, G., Rizzo, N., Facchinetti, F., Dall’Asta, A., Visentin, S., et al. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.01.026 · Cited by 205
Sciascia, S., Hunt, B. J., Talavera-García, E., Lliso-Ribera, G., Khamashta, M. A., & Cuadrado, M. J. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.09.078 · Cited by 201
Perfusion defects after pulmonary embolism: risk factors and clinical significance
Sanchez, O., Helley, D., Couchon, S., Roux, A., Delaval, A., Trinquart, L., Collignon, M. A., Fischer, A., & Meyer, G. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03844.x · Cited by 196
Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms
Erkan, D., Espinosa, G., & Cervera, R. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.08.005 · Cited by 191
Diagnosis and management of the antiphospholipid syndrome
Chaturvedi, S., & McCrae, K. R. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.07.006 · Cited by 195
Antiphospholipid antibodies in patients with COVID‐19: A relevant observation?
Devreese, K. M. J., Linskens, E. A., Benoît, D., & Peperstraete, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14994 · Cited by 190
Lakos, G., Favaloro, E. J., Harris, E. N., Meroni, P. L., Tincani, A., Wong, R. C. W., & Pierangeli, S. S. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33349 · Cited by 182
Pierangeli, S., de Groot, P. G., Dlott, J. S., Favaloro, E. J., Harris, E., Lakos, G., Ortel, T. L., Meroni, P. L., Otomo, K., Pengo, V., et al. (2011) · Lupus · doi:10.1177/0961203310395055 · Cited by 179
Self-citationZuily, S., Regnault, V., Selton‐Suty, C., Eschwège, V., Bruntz, J. F., Bode-Dotto, E., de Maistre, E., Dotto, P., Perret‐Guillaume, C., Lecompte, T., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.028522 · Cited by 177
Zuily, S., Cohen, H., Isenberg, D. A., Woller, S. C., Crowther, M. A., Dufrost, V., Wahl, D. G., Doré, C. J., Cuker, A. C., Carrier, M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14935 · Cited by 160
Self-citationPre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis
Favaloro, E. J., Funk, D. M. A., & Lippi, G. (2012) · Laboratory Medicine · doi:10.1309/lm749bqetkypypvm · Cited by 151
Legault, K., Schünemann, H. J., Hillis, C., Yeung, C. H. T., Akl, E. A., Carrier, M., Cervera, R., Crowther, M. A., Dentali, F., Erkan, D., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14192 · Cited by 150
Self-citationRecent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants
Moore, G. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1364185 · Cited by 149
“2,4,5,13,14,17,20 In addition, although most commercial dRVVTreagents behave similarly, potentially suggesting common manufacturing practices, occasional deviations in behavior occur.”
BackgroundQuality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing
Funk, D. M. A., Lippi, G., & Favaloro, E. J. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1319768 · Cited by 148
Tripodi, A., Cohen, H., & Devreese, K. M. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14846 · Cited by 143
Self-citationTreatment of catastrophic antiphospholipid syndrome
Kazzaz, N. M., McCune, W. J., & Knight, J. S. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000269 · Cited by 134
Acquired hemophilia A: a review of recent data and new therapeutic options
Franchini, M., Vaglio, S., Marano, G., Mengoli, C., Gentili, S., Pupella, S., & Liumbruno, G. M. (2017) · Hematology · doi:10.1080/10245332.2017.1319115 · Cited by 133
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients
Schmidt‐Tanguy, A., Voswinkel, J., Henrion, D., Subra, J. F., Loufrani, L., Rohmer, V., Ifrah, N., & Belizna, C. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12363 · Cited by 132
Diagnosis of antiphospholipid syndrome in routine clinical practice
Gardiner, C., Hills, J., Machin, S., & Cohen, H. (2013) · Lupus · doi:10.1177/0961203312460722 · Cited by 131
Schreiber, K. I., Breen, K. A., Cohen, H., Jacobsen, S., Middeldorp, S., Pavord, S. R., Regan, L., Roccatello, D., Robinson, S. E., Sciascia, S., et al. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1603359 · Cited by 128
Alijotas‐Reig, J., Esteve‐Valverde, E., Anunciación-Llunell, A., Marques-Soares, J. R., Pardos‐Gea, J., & Miró‐Mur, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030675 · Cited by 132
Pengo, V., Ruffatti, A., Tonello, M., Cuffaro, S., Banzato, A., Bison, E., Denas, G., & Padayattil Jose, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12865 · Cited by 126
Self-citationErkan, D., Willis, R., Murthy, V. L., Basra, G., Vega, J., Ruiz‐Limón, P., Carrera, A. L., Papalardo, E., Martínez-Martínez, L.-A., González, E. B., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203622 · Cited by 125
Nuri, E., Taraborelli, M., Andreoli, L., Tonello, M., Gerosa, M., Calligaro, A., Argolini, L. M., Kumar, R., Pengo, V., Meroni, P. L., et al. (2017) · Immunologic Research · doi:10.1007/s12026-016-8812-z · Cited by 123
Self-citationDiagnosis and management of the antiphospholipid syndrome
Cohen, D. B., Berger, S. P., Steup‐Beekman, G. M., Bloemenkamp, K. W. M., & Bajema, I. M. (2010) · BMJ · doi:10.1136/bmj.c2541 · Cited by 127
Radin, M., Sciascia, S., Erkan, D., Pengo, V., Tektonidou, M. G., Ugarte, A., Meroni, P. L., Ji, L., Belmont, M. H., Cohen, H., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.009 · Cited by 121
Self-citationRodriguez-Garcia, J. L., Bertolaccini, M. L., Cuadrado, M. J., Sanna, G., Ateka–Barrutia, O., & Khamashta, M. A. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200614 · Cited by 117
The antiphospholipid syndrome: from pathophysiology to treatment
Negrini, S. M., Pappalardo, F., Murdaca, G., Indiveri, F., & Puppo, F. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0430-5 · Cited by 117
SCIASCIA, S., MURRU, V., SANNA, G., ROCCATELLO, D., KHAMASHTA, M. A., & BERTOLACCINI, M. L. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12014 · Cited by 116
Schouwers, S. M. E., Delanghe, J. R., & Devreese, K. M. J. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2009.09.001 · Cited by 115
Laboratory Diagnosis of Acquired Hemophilia A: Limitations, Consequences, and Challenges
Werwitzke, S., Scharf, R., & Tiede, A. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0034-1390004 · Cited by 114
Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment
Tripodi, A., de Groot, P. G., & Pengo, V. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02362.x · Cited by 114
Self-citationKravvariti, E., Koutsogianni, A., Samoli, E., Sfikakis, P. P., & Tektonidou, M. G. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102491 · Cited by 115
Lupus Anticoagulant-Hypoprothrombinemia Syndrome
Mazodier, K., Arnaud, L., Mathian, A., Costedoat-Chalumeau, N., Haroche, J., Francès, C., Harlé, J., Pernod, G., Lespessailles, É., Gaudin, P., et al. (2012) · Medicine · doi:10.1097/md.0b013e31826b971f · Cited by 112
Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target
Knight, J. S., Meng, H., Coit, P., Yalavarthi, S., Sule, G. J., Gandhi, A. A., Grenn, R. C., Mazza, L. F., Ali, R. A., Renauer, P. A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93897 · Cited by 112
Seed, P. T., Parmar, K., Moore, G. W., Stuart‐Smith, S., Hunt, B. J., & Breen, K. A. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-08-0554 · Cited by 111
Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review
Taha, M., & Samavati, L. (2021) · RMD Open · doi:10.1136/rmdopen-2021-001580 · Cited by 109
Salvan, E., Ross, T. D., Gerosa, M., Andreoli, L., Maina, A., Alijotas-Reig, J., Carolis, S. D., Mekinian, A., Bertero, M. T., Canti, V., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0191 · Cited by 108
The global anti-phospholipid syndrome score in primary APS
Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M. A., & Bertolaccini, M. L. (2015) · Rheumatology · doi:10.1093/rheumatology/keu307 · Cited by 107
Zohoury, N., Bertolaccini, M. L., Rodriguez-Garcia, J. L., Shums, Z., Ateka–Barrutia, O., Sorice, M., Norman, G. L., & Khamashta, M. A. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.170044 · Cited by 107
Shi, H., Zheng, H. W., Yin, Y., Hu, Q., Teng, J., Sun, Y., Liu, H.-L., Cheng, X., Ye, J., Su, Y., et al. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0502 · Cited by 106
Andréoli, L., Chighizola, C. B., Nalli, C., Gerosa, M., Borghi, M. O., Pregnolato, F., Grossi, C., Zanola, A., Allegri, F., Norman, G. L., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39187 · Cited by 105
Lim, W. (2013) · Hematology · doi:10.1182/asheducation-2013.1.675 · Cited by 107
Cohen, D. B., Buurma, A., Goemaere, N. N. T., Girardi, G., le Cessie, S., Scherjon, S. A., Bloemenkamp, K. W. M., de Heer, E., BRUIJN, J. A., & Bajema, I. M. (2011) · The Journal of Pathology · doi:10.1002/path.2893 · Cited by 102
BRODER, A., & PUTTERMAN, C. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120157 · Cited by 102
Pengo, V., Ruffatti, A., Del Ross, T., Tonello, M., Cuffaro, S., Hoxha, A., Banzato, A., Bison, E., Denas, G., Bracco, A., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12264 · Cited by 101
Self-citationPetri, M. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.006 · Cited by 113
Nakashima, M. O., & Rogers, H. J. (2014) · Blood Research · doi:10.5045/br.2014.49.2.85 · Cited by 103
Systemic lupus erythematosus and thrombosis
Bazzan, M., Vaccarino, A., & Marletto, F. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0043-3 · Cited by 100
Senzolo, M., Rodriguez-Castro, K. I., Rossetto, V., Radu, C. M., Gavasso, S., Carraro, P., Zerbinati, P., Sartori, M. T., & Simioni, P. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04824.x · Cited by 99
Antiphospholipid antibody testing and standardization
Devreese, K. M. J. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12234 · Cited by 98
Kershaw, G., Mohammed, S., Lippi, G., & Favaloro, E. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1677018 · Cited by 96
Laboratory testing of anticoagulants: the present and the future
Favaloro, E. J., Lippi, G., & Koutts, J. (2011) · Pathology · doi:10.1097/pat.0b013e32834bf5f4 · Cited by 95
Barbhaiya, M., Zuily, S., Ahmadzadeh, Y., Amigo, M., Avčin, T., Bertolaccini, M. L., Branch, D. W., de Jesús, G. R., Devreese, K. M. J., Francès, C., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24520 · Cited by 95
Self-citationKitchen, S., Adcock, D. M., Dauer, R., Kristoffersen, A., Lippi, G., Mackie, I. J., Marlar, R. A., & Nair, S. C. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13702 · Cited by 95
Dusse, L. M. S., Alpoim, P. N., Silva, J. T., Rios, D. R. A., Brandão, A. H. F., & Cabral, A. C. V. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.024 · Cited by 93
Conti, F., Ceccarelli, F., Perricone, C., Leccese, I., Massaro, L., Pacucci, V. A., Truglia, S., Miranda, F., Spinelli, F. R., Alessandri, C., et al. (2016) · Lupus · doi:10.1177/0961203315627199 · Cited by 93
Devreese, K., Peerlinck, K., & Hoylaerts, M. F. (2010) · Blood · doi:10.1182/blood-2009-09-244426 · Cited by 93
Martinuzzo, M. E., Barrera, L. H., D 'Adamo, M. A., Otaso, J. C., Gimenez, M. I., & Oyhamburu, J. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12138 · Cited by 91
Ramon, I., Mathian, A., Bachelot, A., Hervier, B., Haroche, J., Huong, D. U. L. T., Costedoat-Chalumeau, N., Wechsler, B., Karmali, R., Velkeniers, B., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4300 · Cited by 91
Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease
Aguiar, C. L., & Erkan, D. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13502919 · Cited by 91
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant
Pengo, V., Testa, S., Martinelli, I., Ghirarduzzi, A., Legnani, C., Gresele, P., Passamonti, S. M., Bison, E., Denas, G., Jose, S. P., et al. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.013 · Cited by 89
Self-citationTonello, M., Hoxha, A., Sciascia, S., Cuadrado, M. J., Latino, J. O., Udry, S., Reshetnyak, T. M., Costedoat-Chalumeau, N., Morel, N., Marozio, L., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1632388 · Cited by 89
Self-citationLupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature
Mulliez, S., Keyser, F. D., Verbist, C., Vantilborgh, A., Wijns, W. C., Beukinga, I., & Devreese, K. M. J. (2014) · Lupus · doi:10.1177/0961203314558859 · Cited by 89
Sevim, E., Zisa, D., Andrade, D., Sciascia, S., Pengo, V., Tektonidou, M. G., Ugarte, A., Gerosa, M., Belmont, H. M., Zamorano, M. A. A., et al. (2022) · Arthritis Care & Research · doi:10.1002/acr.24468 · Cited by 88
Self-citationAntiphospholipid syndrome and the heart: A case series and literature review
Denas, G., Jose, S. P., Bracco, A., Zoppellaro, G., & Pengo, V. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.11.003 · Cited by 89
Self-citationChayoua, W., Kelchtermans, H., Gris, J., Moore, G. W., Musiał, J., Wahl, D., de Groot, P. G., de Laat, B., & Devreese, K. M. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14633 · Cited by 89
Litvinova, E., Darnige, L., Kirilovsky, A., Burnel, Y., Luna, G. D., & Dragon‐Durey, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02971 · Cited by 87
Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time
OS, G. M. A. V., de Laat, B., Kamphuisen, P. W., Meijers, J. C. M., & de Groot, P. G. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04395.x · Cited by 87
Strakhan, M., Hurtado-Sbordoni, M., Galeas, J. N., Bakirhan, K., Alexis, K. M., & Elrafei, T. N. (2014) · Case Reports in Hematology · doi:10.1155/2014/704371 · Cited by 86
Antiphospholipid syndrome – an update
Linnemann, B. (2018) · VASA · doi:10.1024/0301-1526/a000723 · Cited by 86
Challenges in the Diagnosis of the Antiphospholipid Syndrome
Devreese, K. M. J., & Hoylaerts, M. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.133678 · Cited by 82
Pediatric Antiphospholipid Syndrome
Cimaz, R., & Descloux, É. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.005 · Cited by 81
Influence of dabigatran and rivaroxaban on routine coagulation assays
Bailleul, E., Châtelain, B., Demulder, A., Devreese, K. M. J., Douxfils, J., Jochmans, K., Mullier, F., Wijns, W., Soumali, M. R., Coucke, W., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0161 · Cited by 80
A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis
Rodriguez-Castro, K. I., Vitale, A., Fadin, M., Shalaby, S., Zerbinati, P., Sartori, M. T., Landi, S., Pettinari, I., Piscaglia, F., Han, G., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001237 · Cited by 79
Conti, F., Fulvia, C., Perricone, C., Massaro, L., Marocchi, E., Francesca, M., Spinelli, F. R., Truglia, S., Alessandri, C., & Valesini, G. (2015) · Mediators of Inflammation · doi:10.1155/2015/328078 · Cited by 79
Valvular Heart Disease in Antiphospholipid Syndrome
Zuily, S., Huttin, O., Mohamed, S., Marie, P., Selton‐Suty, C., & Wahl, D. G. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0320-8 · Cited by 79
Craemer, A. S. D., Musiał, J., & Devreese, K. M. J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13389 · Cited by 78
Metadata
- Authors
- PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G.
- Affiliations
- University of Padua (IT)
- University of Milan (IT)
- University Hospital of Geneva (CH)
- Montefiore Medical Center (US)
- Duke Medical Center (US)
- Corresponding author
- PENGO, V.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 7
- Issue
- 10
- Pages
- 1737-1740
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2069797332
- Cited by
- 1,197
- References
- 21
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 53 · 2023: 55 · 2022: 65 · 2021: 89 · 2020: 99 · 2019: 101 · 2018: 88 · 2017: 82 · 2016: 80 · 2015: 75 · 2014: 81 · 2013: 69 · 2012: 82
- FWCI
- 48.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Keywords
- lupus anticoagulant, patient selection, activated partial thromboplastin time, cut-off values, interpretation of results, diagnostic guidelines
- MeSH terms
- Anticoagulants, Blood Coagulation, Blood Specimen Collection, Female, Humans, Indicators and Reagents, Male, Partial Thromboplastin Time, Phospholipids, Pregnancy, Pregnancy Complications, Hematologic, Prothrombin Time, Specimen Handling, Vitamin K, Artifacts, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
